Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials

Capsule summary: Among patients who participated in randomized clinical trials of omalizumab, no substantial overall increase in the risk of cardiovascular events was observed in the treatment arms compared with placebo. <<29/35 words>>

http://ift.tt/2iyTvGq